Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW. Penack O, et al. Among authors: malladi r. Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. Lancet Haematol. 2020. PMID: 32004485 Review.
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Malladi RK, Peniket AJ, Norton AE, Campbell AJ, Collins GP, Samol J, Eagleton H, Miller E, Morgenstern G, Jones J, Keen-Mcguire A, Barnardo M, Littlewood TJ. Malladi RK, et al. Eur J Haematol. 2004 Aug;73(2):85-92. doi: 10.1111/j.1600-0609.2004.00266.x. Eur J Haematol. 2004. PMID: 15245506 Clinical Trial.
Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant.
Medd P, Monk I, Danby R, Malladi R, Clifford R, Ellis A, Roberts D, Hatton C, Vyas P, Littlewood T, Peniket A. Medd P, et al. Among authors: malladi r. Int J Hematol. 2011 Sep;94(3):266-278. doi: 10.1007/s12185-011-0920-x. Epub 2011 Sep 7. Int J Hematol. 2011. PMID: 21898174
Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C. Nikolousis E, et al. Among authors: malladi r. Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5. Leuk Res. 2013. PMID: 23395505 Clinical Trial.
Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
Robinson SP, Boumendil A, Finel H, Blaise D, Poiré X, Nicolas-Virelizier E, Or R, Malladi R, Corby A, Fornecker L, Caballero D, Pohlreich D, Nagler A, Thieblemont C, Finke J, Bachy E, Vincent L, Schroyens W, Schouten H, Dreger P. Robinson SP, et al. Among authors: malladi r. Bone Marrow Transplant. 2016 Mar;51(3):365-71. doi: 10.1038/bmt.2015.286. Epub 2015 Nov 30. Bone Marrow Transplant. 2016. PMID: 26618550 Clinical Trial.
Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A. Genadieva-Stavrik S, et al. Among authors: malladi r. Ann Oncol. 2016 Dec;27(12):2251-2257. doi: 10.1093/annonc/mdw421. Epub 2016 Oct 24. Ann Oncol. 2016. PMID: 28007754 Free article.
The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.
Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK, Douglas KW, Maher T, Guest J, Hartlett L, Fisher AJ, Child F, Scarisbrick JJ. Alfred A, et al. Among authors: malladi rk. Br J Haematol. 2017 Apr;177(2):287-310. doi: 10.1111/bjh.14537. Epub 2017 Feb 21. Br J Haematol. 2017. PMID: 28220931 Free PMC article.
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S, Montoto S, Boumendil A, Finel H, Masszi T, Jindra P, Nemet D, Fuhrmann S, Beguin Y, Castagna L, Ferrara F, Capria S, Malladi R, Moraleda JM, Bloor A, Ghesquières H, Meissner J, Sureda A, Dreger P. Akhtar S, et al. Among authors: malladi r. Am J Hematol. 2018 Jan;93(1):40-46. doi: 10.1002/ajh.24927. Epub 2017 Nov 9. Am J Hematol. 2018. PMID: 28971503 Free article.
Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A. Bazarbachi A, et al. Among authors: malladi r. Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22. Br J Haematol. 2018. PMID: 29468647 Free article. Clinical Trial.
92 results